MMH-407 clinical trials
Also written MMH-407.
How each study uses MMH-407 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MMH-407 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test MMH-407, phase 3 first.
- Dec 2026Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisPhase 3 · Materia Medica Holding
Studies
Open first, then newest update. How each study uses MMH-407 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult PatientsRecruitingPhase 3Materia Medica HoldingNCT07650227Written as Raphamin
- The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult PatientsRecruitingPhase 3Materia Medica HoldingNCT06901297Written as Raphamin
- Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 YearsRecruitingPhase 3Materia Medica HoldingNCT06715891Written as Raphamin
- Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial CystitisActive, not recruitingPhase 3Materia Medica HoldingNCT06284265Written as Raphamin
- Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired PneumoniaCompletedPhase 3Materia Medica HoldingNCT06263881Written as Raphamin
- Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in OutpatientsCompletedPhase 3Materia Medica HoldingNCT05364671Written as Raphamin
- Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years OldCompletedPhase 3Materia Medica HoldingNCT04918771Written as Raphamin
- Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient AdultsSuspendedPhase 3Materia Medica HoldingNCT04250311Written as MMH-407
- Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral InfectionCompletedPhase 3Materia Medica HoldingNCT04244084Written as MMH-407